Its glucagon receptor activity also makes it a subject of interest in hepatic fat research independent of body weight effects
June 6, 2025: Novo Nordisk Asked to Add NAION, Which Can Cause Blindness, to Ozempic Warning Label The European Medicines Agency has concluded that taking Ozempic and other medications that contain semaglutide may increase someones risk of developing NAION
And the extended titration approach, maintaining each step for six weeks instead of four, dramatically improves tolerability for sensitive individuals
Pantalone, DO, ECNU Incretin-based drug therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic peptide and GLP-1 receptor agonists are rapidly becoming first-line options for treating type 2 diabetes
131,132,133 Additionally, GLP-1 helps to delay gastric emptying and suppress appetite, aiding in weight management
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity
